as 03-28-2025 4:00pm EST
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Founded: | 1996 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 14.2B | IPO Year: | 2020 |
Target Price: | $41.60 | AVG Volume (30 days): | 4.2M |
Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
EPS: | 1.91 | EPS Growth: | -24.54 |
52 Week Low/High: | $24.05 - $34.20 | Next Earning Date: | 05-08-2025 |
Revenue: | $2,263,576,000 | Revenue Growth: | -3.86% |
Revenue Growth (this year): | 33.46% | Revenue Growth (next year): | 4.44% |
RPRX Breaking Stock News: Dive into RPRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Insider Monkey
3 days ago
GlobeNewswire
a month ago
Insider Monkey
a month ago
Morningstar Research
a month ago
Morningstar Research
a month ago
GlobeNewswire
a month ago
GuruFocus.com
a month ago
The information presented on this page, "RPRX Royalty Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.